A promotional GSK-sponsored symposium invited three experts to discuss their main considerations when selecting an inhaled corticosteroid (ICS)/inhaled long-acting β2-agonist (LABA) combination for patients with moderate asthma. Ashley Woodcock, Professor of Respiratory Medicine, University of Manchester; and Consultant Physician at The North-West Lung Centre, Wythenshawe Hospital, Manchester, UK, explained why timely assessment is critical for ICS/LABA initiation.
EMJ Respiratory 12 [Supplement 3] . 2024
October 2024
Latest articles
All articles
12 Mins
12th
December
Clinical Applications of Hyperpolarised Xenon-129 MRI
The editor’s pick for this issue is a review article discussing the promise of hyperpolarised xenon MRI, a non-invasive imaging technique…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
10 Mins
12th
December
IL-5 in Type 2 Inflammatory Diseases
Type 2 inflammation is involved in severe asthma (SA), chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
6 Mins
22nd
October
Precision Strikes: Personalising Stage IIIA Lung Cancer Treatment with Targeted and Immune Therapies
The treatment landscape for potentially surgically resectable Stage IIIA non-small cell lung cancer (NSCLC), particularly for…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.